Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 2Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 13Carcinoma, Hepatocellular 6Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 2Rectal Neoplasms 2Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Astrocytoma 2Vipoma 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Recurrence 1Progression Free Survival 1Oropharyngeal Neoplasms 1Oesophagogastric Cancer 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Mesothelioma 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1Laryngeal Neoplasms 1Insulinoma 1Inflammatory Breast Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Taxes 1Pharmacogenomic Testing 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Adenocarcinoma, Bronchiolo-Alveolar × Bevacizumab × Clear all
NCT00021060 2013-02-27

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
842 enrolled
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡